Your shopping cart is currently empty

Taurolithocholic Acid 3-sulfate sodium salt is a GPR39 agonist. In the absence of Zn²⁺, its EC50 values are 71.6 μM and 69.4 μM in M39-20 and hGPR39-2 cells, respectively; in the presence of Zn²⁺, the values are 9 μM and 9.6 μM, respectively. Taurolithocholic Acid 3-sulfate sodium salt activates the GPR39 receptor and mediates intracellular calcium signaling pathways independently of the Zn²⁺-binding sites H17 and H19, and can be used in research on gallbladder-related diseases.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $63 | - | In Stock | |
| 5 mg | $158 | - | In Stock | |
| 10 mg | $237 | - | In Stock | |
| 25 mg | $392 | - | In Stock | |
| 50 mg | $585 | - | In Stock | |
| 100 mg | $833 | - | In Stock |
| Description | Taurolithocholic Acid 3-sulfate sodium salt is a GPR39 agonist. In the absence of Zn²⁺, its EC50 values are 71.6 μM and 69.4 μM in M39-20 and hGPR39-2 cells, respectively; in the presence of Zn²⁺, the values are 9 μM and 9.6 μM, respectively. Taurolithocholic Acid 3-sulfate sodium salt activates the GPR39 receptor and mediates intracellular calcium signaling pathways independently of the Zn²⁺-binding sites H17 and H19, and can be used in research on gallbladder-related diseases. |
| Targets&IC50 | GPR39 without Zn2+ (human):69.4 μM (EC50), M39-20 cells (with Zn²⁺):9 μM (EC50), M39-20 cells (without Zn2+):71.6 μM (EC50), GPR39 with Zn2+ (human):9.6 μM (EC50) |
| In vitro | In the absence of Zn²⁺, the EC50 values of Taurolithocholic Acid 3-sulfate sodium salt on M39-20 and hGPR39-2 cells were 71.6 μM and 69.4 μM, respectively; in the presence of Zn²⁺, the EC50 values were 9 μM and 9.6 μM, respectively. |
| Synonyms | Taurolithocholic acid 3-sulfate disodium, 3-Sulfotaurolithocholic acid disodium |
| Molecular Weight | 607.73 |
| Formula | C26H43NNa2O8S2 |
| Cas No. | 64936-83-0 |
| Smiles | C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(NCCS(=O)([O-])=O)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@](C[C@@H](CC4)OS(=O)([O-])=O)([H])CC3)C.[Na+].[Na+] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | ||||||||||
| Solubility Information | Ethanol: 1 mg/mL (1.65 mM), Sonication is recommended. DMSO: 20 mg/mL (32.91 mM), Sonication is recommended. PBS (pH 7.2): 1 mg/mL (1.65 mM), Sonication is recommended. DMF: 25 mg/mL (41.14 mM), Sonication is recommended. | ||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (1.65 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||
Solution Preparation Table | |||||||||||
Ethanol/PBS (pH 7.2)/DMSO/DMF
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | |||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.